{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"55554","value":"65071"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"AUC was predicted using population pharmacokinetic model.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Isatuximab 20 mg/kg IV infusion, QW for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1), and then Q2W (i.e., on Day 1 and 15) for subsequent treatment cycles (each cycle of 28 days) until unacceptable AEs, disease progression, or any other reason for discontinuation whichever occurs first (maximum duration of exposure: 248 weeks).","id":"OG000","title":"Phase 2: Isatuximab 20 mg/kg"}],"paramType":"MEAN","populationDescription":"Analysis was performed on PK population. Here, \"Overall number of participants analyzed\" = participants with available data for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Multiple timepoints from Cycle 1 to Cycle 10","title":"Phase 2: Area Under the Plasma Concentration Versus Curve Over the Dosing Interval (AUC1-Week) After First Infusion of Isatuximab","type":"SECONDARY","unitOfMeasure":"micrograms * hours per milliliter"}